San Diego-primarily based Viking Therapeutics marked by itself as a significant competitor from the weight loss drug marketplace in February just after revealing promising information from the mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when specified as a weekly injection As well